Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06172335

Effects of Cetoleic Acid on Atherosclerosis (Ketolinsyre's Effekt på Aterosklerose)

In this Randomized Controlled Trial (RCT) we want to study the effect of an oil with high concentrations of cetoelic acid (C22:n1-11) (intervention) compared to supplements with a low concentration of cetoleic acid (control), but with equivalent content of EPA og DHA, on plasma levels of epa and dha as well as atherosclerotic markers, glucose, c-peptide and triglycerides in a patient group with a metabolically unfavorable phenotype.

Our primary endpoints are changes in the concentration of EPA and DHA in plasma.

Recruiting

Interested in participating?

Request Info

Key information

Age range

20 year–70 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Oslo University Hospital

Oslo, Norway

Location status: Recruiting

Location contact

Kirsten B Holven, Professor

CONTACT

About this study

This is a randomized double-blinded controlled trial (randomized 1:1). Study population: men and women 20-70 years with a metabolically unfavorable phenotype defined as: triglycerides > 1.7 mmol/L and waist measurement > 80 cm (women) and > 94 cm (men).

Study design:

  • 3 weeks run-in-period where all participants consume control capsules every morning.
  • Randomization intervention: control (1:1). All participants consume their capsules (control or intervention) for 4 weeks.

The intervention oil is consists of an oil high in cetoleic acid and the control oil is low in cetoleic acid. Both the intervention oil and the control oil are a mix of different oils; fish oils, olive oil, "high-oleic sunflower oil" and rapeseed oil so that the content of EPA, DHA and ALA is similar in the two oils.

Power calculation and sample size:

It was expected a difference of 15% in n-3 between the groups after the intervention (Østbye et al. 2019, doi:10.1017/S0007114519001478).

The level of significance was set to 5% (two-sided) and the power to 80%. A total of thirty-eight subjects were required to participate in the study, but a high dropout rate was expected (20%) and it was considered necessary to include a total of seventy (n=70) subjects (thirty-five per arm).

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Triglycerides > 1.7 mmol/L
  • Waist measurement > 80 cm (women) and > 94 cm (men)

Exclusion criteria

  • Chronic disease (liver/kidney/metabolism)
  • Ongoing active cancer treatment
  • Excessive alcohol consumption (>40g/day)
  • Pregnant/breastfeeding or planned pregnancy during the intervention
  • High intake of fish (>3 weekly meals)
  • Level of free thyroxine (T4) and triiodothyronine (T3) outside reference ranges.
  • Hypertension (≥ 160/ 100 mmHg)
  • Total cholesterol > 7.8 mmol/L
  • Blood donation during the intervention period
  • Difficulty following the protocol
  • Smoking or sniffing
  • Regular use (> 1 day/week) of anti-inflammatory drugs
  • Regular use of omega-3 supplements/cod liver oil
  • Drug use other than stable use of statins, hypertension drugs (Ca antagonists, diuretics and beta blockers).
  • Hormonal treatment excluding stable use of thyroxine and birth control pills/contraceptive rod

Treatment and study plan

Cetoleic acid

Dietary Supplement

Very long monounsaturated fatty acid (C22:1n-11)

Control oil

Dietary Supplement

Mix of oils with low cetoleic acid content

Primary outcomes

  1. EPA and DHA in plasma

    Time frame: 4 weeks intervention

    EPA and DHA concentration in plasma measured at baseline and after 4 week intervention (and as a "control measurement" at the screening visit)

Secondary outcomes

  1. Lipid profile

    Time frame: 4 weeks intervention

    Plasma levels of triglycerides, total cholesterol, LDL cholesterol, HDL cholesterol, apolipoproteins (apoB and apoA), and Lp(a)

  2. Glucose

    Time frame: 4 weeks intervention

    Serum levels of glucose

  3. Inflammatory markers

    Time frame: 4 weeks intervention

    The concentration of circulating levels of inflammatory markers

  4. Gene expression, metabolome and lipidome

    Time frame: 4 weeks intervention

    Changes in PBMC (peripheral blood mononuclear cell) gene expression profile. Changes in plasma metabolome and lipidome profile. Changes in PBMC epitranscriptome, as a regulator of the gene expression profile

  5. Resolvin

    Time frame: 4 weeks intervention

    Blood levels of resolvin (omega- 3 derivates) concentration

  6. C-peptid

    Time frame: 4 weeks intervention

    serum levels of C-peptid

Study contacts

Contact information is provided by the study sponsor or research team.

Iselin S. Holen, MSc

CONTACT

[email protected]

+4722894882

Kirsten B. Holven, PhD

CONTACT

[email protected]

+4722851361

Sponsors and collaborators

Lead sponsor

Oslo University Hospital

Other

Collaborators

  • University of Oslo

Registry information

Official study title

Effects of Ketolic Acid on Atherosclerosis Markers in High-risk Patients With Metabolic Syndrome (Effekt av Ketolinsyre på aterosklerosemarkører i høyrisikopasienter Med Metabolsk Syndrom)

Important dates

Study start
2024
Primary completion
2024
Study completion
2027
First posted
Dec 15, 2023
Registry last updated
Jan 16, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.